Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.[1][2]
Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.[3]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.21.97.217